Author Affiliations: Department of Ophthalmology,
Flinders University of South Australia, Adelaide, Australia.
Molecular medicine offers promise for the prevention of vision loss
caused by ocular neovascularization in diabetic retinopathy and exudative
age-related macular degeneration (ARMD). During the past decade, significant
advances have been made in angiogenesis research, such that the understanding
about new vessel formation in disease has increased considerably. This knowledge
has led to the development of numerous inhibitors of angiogenesis. Among a
host of novel therapeutics for ocular neovascularization, 2 inhibitors of
the angiogenic agent vascular endothelial growth factor (VEGF)—pegaptanib
sodium and ranibizumab—are poised for imminent clinical application.
However, the need for repeated intraocular injection of these agents and the
potential for local and systemic adverse effects may pose hurdles for these
van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of Ocular NeovascularizationPromises and Potential Problems. JAMA. 2005;293(12):1509-1513. doi:10.1001/jama.293.12.1509